내시경적 역행 담췌관 조영술(ERCP) 시장 : 2026년까지의 세계 예측

출판 : MarketsandMarkets(마켓츠앤드마켓츠)출판년월 : 2022년03월

내시경적 역행 담췌관 조영술(ERCP) 시장 : 제품 (상부 소화관 내시경, 스텐트, 풍선, 카테터, 바구니), 절차 (담관 괄약근 절개술, 스텐트 유치술, 췌장 괄약근 절개술), 최종 사용자 (병원) – 2026년까지의 세계 예측

Endoscopic Retrograde Cholangiopancreatography/ERCP Market by Product (Upper GI endoscopes, Stent, Balloons, Catheters, Baskets), Procedure (Biliary Sphincterotomy & Stenting, Pancreatic Sphincterotomy), End User (Hospitals) – Global Forecast to 2026

페이지수 231
도표수 200
구성 영문조사보고서
가격

리포트목차    주문/문의    납기/라이센스안내

Sample Request

내시경적 역행 담췌관 조영술(ERCP) 시장은 2021년에 13억 달러, 2026년까지는 20억 달러에 이르며 예측 기간의 CAGR은 9.6%가 될 것으로 예측된다。

MarketsandMarkets「내시경적 역행 담췌관 조영술(ERCP) 시장 제품 (상부 소화관 내시경, 스텐트, 풍선, 카테터, 바구니), 절차 (담관 괄약근 절개술, 스텐트 유치술, 췌장 괄약근 절개술), 최종 사용자 (병원) – 2026년까지의 세계 예측 – Endoscopic Retrograde Cholangiopancreatography/ERCP Market by Product (Upper GI endoscopes, Stent, Balloons, Catheters, Baskets), Procedure (Biliary Sphincterotomy & Stenting, Pancreatic Sphincterotomy), End User (Hospitals) – Global Forecast to 2026」는 세계의 내시경적 역행 담췌관 조영술(ERCP) 시장을 조사하고 주요 세그먼트별로 실시한 분석 및 예측 결과를 제공하고 있습니다。

MarketsandMarkets 분석 포인트

  • 촉진 요인: 암 이환율 증가
  • 저해 요인: 비싼 내시경 역행성 담췌관 조영 장치
  • 기회: 신흥 경제권의 의료 분야 발전

주요 조사 범위

제품

  • 내시경
  • 내시경 치료 장치
    • 괄약근 절개도
    • 초음파 신석 파쇄기
    • 스텐트
    • 캐뉼라
    • 포셉
    • 스네어
    • 카테터
    • 가이딩 와이어
    • 풍선
    • 바구니
  • 가시화 장치
  • 에너지 기기
  • 기타

수술

  • 담도 괄약근 절개술
  • 담관 스텐트 고정
  • 담관 확장
  • 췌장 괄약근 절개술
  • 췌관 스텐트 유치
  • 췌관 확장

최종 사용자

  • 병원
  • 외래 수술 센터 및 클리닉
  • 기타 최종 사용자

지역

  • 북미
    • 미국
    • 캐나다
  • 유럽
    • 프랑스
    • 독일
    • 영국
    • 이탈리아
    • 스페인
    • 기타 유럽
  • 아시아 태평양 지역
    • 일본
    • 중국
    • 인도
    • 오스트레일리아
    • 기타 아시아 태평양 국가
  • 라틴 아메리카
  • 중동
  • 아프리카

Report Description

The global endoscopic retrograde cholangiopancreatography market is projected to reach USD 2.0 billion by 2026 from USD 1.3 billion in 2021, at a CAGR of 9.6% during the forecast period. The growth of this market is majorly attributed to factors such as the rising incidence of cancer, increasing investments by governments and healthcare organizations to improve endoscopy research, growing focus on investments by hospitals for advanced endoscopy instruments, and the increasing preference for minimally invasive surgeries.

Covid-19 Impact on the Endoscopic retrograde cholangiopancreatography Market

The COVID-19 pandemic has resulted in a global crisis. Surgeons and patients visiting hospitals for various treatments are at increased risk of getting infected by COVID-19. Most of the gastrointestinal procedures were suspended, leading to a decrease in device-based treatments such as ERCP. Around 40–50% of endoscopy procedures were canceled in major hospitals across Germany. According to a research study, the COVID-19 pandemic significantly reduced ERCP procedures. The success rate was also lowered due to restrictions on endoscopic services in the UK and worldwide. This negatively impacted the ERCP market. Moreover, endoscopy is considered an aerosol-generating procedure, which imposes the risk of transmission to health care professionals. Nevertheless, the providers use PPE kits and further precaution measures to continue endoscopy procedures.

The sales of disposable endoscopes have risen in contrast to autoclavable endoscopes as many hospitals and clinics lack the resources and manpower to adhere to and implement the stringent COVID-19 guidelines put forth by the European Society for Gastrointestinal Endoscopy (ESGE) and the German Respiratory Society (Deutsche Gesellschaft für Pneumologie und Beatmungsmedizin or DGP). The use of negative pressure suites and personal protective kits and spatial separation of wards are recommended to avoid the risk of infection. Additionally, a research study revealed that the use of Enhanced Personal Protective Equipment (EPPE) had no negative effects on ERCP performance in this patient group. This meant that ERCP could be effectively performed under EPPE. As a result, the overall cost of endoscopic treatment has increased. These factors have restrained the growth of the ERCP market. However, with the rollout of vaccines worldwide, the market will likely recover in the coming years.

Endoscopic retrograde cholangiopancreatography Market Dynamics

Driver: Rising incidence of cancer

Nowadays, the global incidence of cancer is increasing. According to the WHO, cancer is the second-leading cause of death globally and was responsible for 9.6 million deaths in 2018. According to the American Cancer Society’s estimates, about 41,260 new cases of liver cancer and intrahepatic bile duct cancer will be diagnosed in 2022 in the US. Liver cancer incidence rates have more than tripled since 1980, while the death rates have more than doubled during this time. In 2021, around 60,430 new pancreatic cases were diagnosed in the US. In the UK (2016-2018), around 10,500 new pancreatic cancer cases and 6,200 liver cancer cases every year. Globally, 458,918 new cases of pancreatic cancer were reported in 2018, and 355,317 new cases are estimated to occur until 2040 (GLOBOCAN 2018 estimates).
Since ERCP is often used as a diagnostic tool in hepatic, bile duct, and pancreatic cancers, the rising incidence of these cancers is directly related to the impact on the ERCP market

Restraint: High costs of endoscopic retrograde cholangiopancreatography devices

One of the most pertinent restraining factors for the market is the high costs of ERCP equipment and procedures. The average selling price of a duodenoscope is around USD 31,500 (Non- HD) to USD 37,000 (HD). This high price, combined with the long procedure time, makes this unfavorable. Additionally, an interview conducted with an expert in the ERCP market cost can be one of the leading reasons for the procedure not being easily accessible and affordable to many small-scale end users, which cater to a large population, especially in developing countries.

Opportunity: The growing healthcare sector in emerging economies

Brazil, Russia, India, China, and South Africa (BRICS) are among the fastest-growing economies globally. According to World Economic Forum, the emerging economies accounted for around one-third of the global healthcare expenditure in 2021. More than half of the world’s population resides in India and China, owing to which these countries are home to the highest number of patients.

The increasing burden of cancer, rapid improvements in healthcare infrastructure, the rapid growth of medical tourism, and the presence of flexible regulation in these countries encourage players in the endoscopy equipment market to expand their presence in emerging countries.

Several endoscopy equipment manufacturers are currently setting up their facilities in the Asia Pacific, the Middle East, and Latin America. Key players such as KARL STORZ have already set up their manufacturing and R&D facilities in these countries. In addition, market saturation in developed regions, such as North America and Europe, will compel manufacturers to focus on emerging markets in the coming years.

These factors are expected to offer significant growth opportunities for the ERCP market.

By product type segment, the endotherapy devices segment accounted for the largest market share during the forecast period.

Based on products, the endoscopic retrograde cholangiopancreatography market has been segmented into endoscopes, endotherapy devices, visualization systems, energy devices, and others. The factors attributing to the large revenue of the endotherapy devices segment include the growing preference for minimally invasive surgeries and the increasing prevalence of gastrointestinal conditions.

Sphincterotomes accounted for the largest market share in the conventional devices segment during the forecast period.

In the endotherapy devices segment, sphincterotomes accounted for the largest market share during the forecast period. This can be attributed to the increasing incidence of pancreatic duct and bile duct stones and the growing geriatric population leading to an increase in biliary disorders.

Asia-Pacific and Latin America are the fastest-growing markets for endoscopic retrograde cholangiopancreatography market during the forecast period.
The Asia Pacific and Latin America markets are projected to grow at the highest CAGR during the forecast period. The high growth in this regional market can be attributed to the existence of a well-developed healthcare system in Japan with universal health insurance coverage and the focus of countries such as China and India on healthcare infrastructure improvements to serve large populations of patients with critical illnesses, including cancer, and tumors. Additionally, governments in several Latin American countries focus on improving their respective healthcare systems. The healthcare sector in Brazil has undergone significant changes, making the country one of the world’s most promising and attractive markets.

Key Market Players

The major players in the global endoscopic retrograde cholangiopancreatography market include Olympus Corporation (Japan), CONMED Corporation (US), Fujifilm Holdings Corporation (Japan), HOYA Corporation (Japan), KARL STORZ SE & Co. KG (Germany), Ambu A/S (Denmark), Boston Scientific Corporation (US), Johnson & Johnson (US), Medtronic, PLC (Ireland), Cook Medical (US), and B. Braun Melsungen AG (Germany).

Other players in the market include Hobbs Medical, Inc. (US), STERIS PLC (US), Merit Medical Systems, Inc. (US), TeleMed Systems, Inc. (US), Changzhou Health Microport Medical Device Co., LTD. (China), Medi-Globe GmbH (Germany), Taewoong Medical Co., Ltd. (South Korea), Huger Medical Instrument Co., Ltd. (China), IntroMedic Co., Ltd. (Republic of Korea), SonoScape Medical Corporation (China), Shanghai AOHUA Photoelectricity Endoscope Co., Ltd. (China), Ottomed (India), Kimberly-Clark Corporation (US), and Shaili Endoscopy (India)

Scope of the Report

Report Metric

Details

Market size available for years 2019–2026
Base year considered 2020
Forecast period 2021–2026
Forecast units Value (USD)
Segments covered Product, procedure, end-user, and region
Geographies covered North America, Europe, Asia Pacific, Latin America, Middle East, and Africa
Companies covered
  • Olympus Corporation (Japan)
  • CONMED Corporation (US)
  • Fujifilm Holdings Corporation (Japan)
  • HOYA Corporation (Japan)
  • KARL STORZ SE & Co. KG (Germany)
  • Ambu A/S (Denmark)
  • Boston Scientific Corporation (US)
  • Johnson & Johnson (US)
  • Medtronic, PLC (Ireland)
  • Cook Medical (US)
  • B. Braun Melsungen AG (Germany)
  • Hobbs Medical, Inc. (US)
  • STERIS PLC (US)
  • Merit Medical Systems, Inc. (US)
  • TeleMed Systems, Inc. (US)
  • Changzhou Health Microport Medical Device Co., LTD. (China)
  • Medi-Globe GmbH (Germany)
  • Taewoong Medical Co., Ltd. (South Korea)
  • Huger Medical Instrument Co., Ltd. (China)
  • IntroMedic Co., Ltd. (Republic of Korea)
  • SonoScape Medical Corporation (China)
  • Shanghai AOHUA Photoelectricity Endoscope Co., Ltd. (China)
  • Ottomed (India)
  • Kimberly-Clark Corporation (US)
  • Shaili Endoscopy (India)

The research report categorizes the Endoscopic retrograde cholangiopancreatography market into the following segments and subsegments:

Product

  • Endoscopes
  • Endotherapy Devices
    • Sphincterotomes
    • Lithotripter
    • Stents
    • Cannulas
    • Forceps
    • Snares
    • Catheters
    • Guiding Wires
    • Balloons
    • Baskets
  • Visualization Systems
  • Energy Devices
  • Others

Procedure

  • Biliary Sphincterotomy
  • Biliary Stenting
  • Biliary Dialtation
  • Pancreatic Sphincterotomy
  • Pancreatic Duct Stenting
  • Pancreatic Duct Dilatation

End User

  • Hospitals
  • Ambulatory Surgery Centres & Clinics
  • Other End Users

Region

  • North America
    • US
    • Canada
  • Europe
    • France
    • Germany
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • Rest of Asia Pacific
  • Latin America
  • Middle East
  • Africa

Recent Developments

  • In January 2022, Cook Medical (US) launched an endoscopic clipping device, namely Instinct Plus, which is compatible through a duodenoscope, has applications for defect closure, anchoring procedures and prophylactic clipping in the gastrointestinal (GI) tract.
  • In May 2021, STERIS PLC (US) acquired Cantel Medical (US) which enabled STERIS Healthcare to expand its product portfolio and cater to customers worldwide.
  • In March 2021, Fujifilm Holdings Corporation (Japan) acquired Hitachi, Ltd.’s Diagnostic Imaging-related Business (Japan), adding to the former’s stronghold in the healthcare business.
  • In October 2020, Olympus Corporation (Japan) launched two endotherapy devices, StoneMasterV and VorticCatchV, to increase the efficiency in bile duct stone management and retrieval for ERCP announced a partnership with Holberg to develop and distribute the Autoscore algorithm.

 

Frequently Asked Questions (FAQ)

Which are the top industry players in the global endoscopic retrograde cholangiopancreatography market?

The major players in the global endoscopic retrograde cholangiopancreatography market include Olympus Corporation (Japan), CONMED Corporation (US), Fujifilm Holdings Corporation (Japan), HOYA Corporation (Japan), KARL STORZ SE & Co. KG (Germany), Ambu A/S (Denmark), Boston Scientific Corporation (US), Johnson & Johnson (US), Medtronic, PLC (Ireland), Cook Medical (US), and B. Braun Melsungen AG (Germany).

Which endoscopic retrograde cholangiopancreatography products & services have been included in this report?

This report includes the following products:

  • Product
  • Endoscopes
  • Endotherapy Devices
  • Sphincterotomes
  • Lithotripter
  • Stents
  • Cannulas
  • Forceps
  • Snares
  • Catheters
  • Guiding Wires
  • Balloons
  • Baskets
  • Visualization Systems
  • Energy Devices
  • Others

Which geographical region is dominating the endoscopic retrograde cholangiopancreatography market?

The global endoscopic retrogarde cholagipancretography market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America accounted for the largest share of the endoscopic retrograde cholangiopancreatography market in 2020. Factors such the increasing prevalence of cancer, high investments by hospitals to purchase new ERCP equipment, and a strong focus on research activities to improve endoscopy techniques.


목차

TABLE OF CONTENTS

1 INTRODUCTION (Page No. – 29)
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
FIGURE 1 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET
1.3.2 YEARS CONSIDERED
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS

2 RESEARCH METHODOLOGY (Page No. – 34)
2.1 RESEARCH DATA
FIGURE 2 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
FIGURE 3 PRIMARY SOURCES
2.1.2.1 Key data from primary sources
2.1.2.2 Key industry insights
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS (ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET)
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION
2.2 MARKET SIZE ESTIMATION
FIGURE 6 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
FIGURE 7 REVENUE SHARE ANALYSIS ILLUSTRATION: OLYMPUS CORPORATION
FIGURE 8 SUPPLY-SIDE MARKET SIZE ESTIMATION: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET (2020)
FIGURE 9 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES FOR THE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET (2021–2026)
FIGURE 10 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
FIGURE 11 TOP-DOWN APPROACH
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 12 DATA TRIANGULATION METHODOLOGY
2.4 MARKET SHARE ESTIMATION
2.5 STUDY ASSUMPTIONS
2.6 LIMITATIONS
2.6.1 METHODOLOGY-RELATED LIMITATIONS
2.7 RISK ASSESSMENT
2.8 ASSESSMENT OF IMPACT OF COVID-19 ON ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET

3 EXECUTIVE SUMMARY (Page No. – 48)
FIGURE 13 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2021 VS. 2026 (USD MILLION)
FIGURE 14 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2021 VS. 2026 (USD MILLION)
FIGURE 15 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2021 VS. 2026 (USD MILLION)
FIGURE 16 GEOGRAPHICAL SNAPSHOT OF THE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET

4 PREMIUM INSIGHTS (Page No. – 51)
4.1 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET OVERVIEW
FIGURE 17 INCREASING INCIDENCE OF CANCER AND THE GROWING PREFERENCE FOR MINIMALLY INVASIVE SURGERIES ARE THE KEY FACTORS DRIVING MARKET GROWTH
4.2 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES
FIGURE 18 CHINA TO WITNESS THE HIGHEST GROWTH IN THE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET DURING THE FORECAST PERIOD
4.3 NORTH AMERICA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT AND COUNTRY (2020)
FIGURE 19 THE ENDOSCOPES SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE ERCP MARKET IN NORTH AMERICA FOR 2020
4.4 REGIONAL MIX: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET (2021–2026)
FIGURE 20 THE ASIA PACIFIC AND LATIN AMERICA REGIONS ARE EXPECTED TO REGISTER THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD (2021–2026)
4.5 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET: DEVELOPED VS. DEVELOPING MARKETS
FIGURE 21 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH DURING THE FORECAST PERIOD

5 MARKET OVERVIEW (Page No. – 55)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 22 MARKET DYNAMICS: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET
5.2.1 MARKET DRIVERS
5.2.1.1 Rising incidence of cancer
FIGURE 23 GLOBAL AGE-STANDARDIZED INCIDENCE RATES OF PANCREATIC CANCER, 2020
5.2.1.2 Increasing investments, funds, and grants by governments and healthcare organizations to improve endoscopy research
TABLE 1 MAJOR DEVELOPMENTS
5.2.1.3 Growing focus on investments by hospitals for advanced endoscopy instruments
TABLE 2 SOME EXAMPLES OF INVESTMENTS BY HOSPITALS FOR ENDOSCOPY INSTRUMENTS
5.2.1.4 Increasing preference for minimally invasive surgeries
FIGURE 24 ENDOSCOPIC GLOBAL MINIMALLY INVASIVE MARKET SIZE (2019-2030)
5.2.2 MARKET RESTRAINTS
5.2.2.1 High costs of endoscopic retrograde cholangiopancreatography devices
5.2.2.2 Development of other procedures like EUS and MRCP
5.2.2.3 Shortage of trained physicians and endoscopists
5.2.3 MARKET OPPORTUNITIES
5.2.3.1 The growing healthcare sector in emerging economies
5.2.3.2 Increasing adoption of single-use endoscopy instruments
5.2.4 MARKET CHALLENGES
5.2.4.1 Product recalls witnessed by major market players
TABLE 3 LIST OF PRODUCT RECALLS
5.2.4.2 Side-effects and infections (like post-ERCP pancreatitis) caused by duodenoscopy products

6 INDUSTRY INSIGHTS (Page No. – 63)
6.1 INTRODUCTION
6.2 TECHNOLOGY TRENDS
6.2.1 ARTIFICIAL INTELLIGENCE IN GI ENDOSCOPY
TABLE 4 AI SYSTEMS AND OTHER RELATED FUNCTIONS
6.2.2 SINGLE-USE ENDOSCOPES
TABLE 5 ADVANTAGES OF DISPOSABLE OR SINGLE-USE ENDOSCOPES OVER REUSABLE ENDOSCOPES
6.2.3 ROBOT-ASSISTED ENDOSCOPES
TABLE 6 ROBOT-ASSISTED ENDOSCOPY PRODUCTS
6.3 INDUSTRY TRENDS
6.3.1 FAVOURABLE REIMBURSEMENT SCENARIO FOR SINGLE-USE DEVICES
6.4 PRICING ANALYSIS
TABLE 7 AVERAGE SELLING PRICE OF FLEXIBLE HD AND NON-HD DUODENOSCOPE (USD)
TABLE 8 US: AVERAGE COST OF ERCP PROCEDURES, 2020 (USD)
6.5 VALUE CHAIN ANALYSIS
FIGURE 25 VALUE CHAIN ANALYSIS: MAXIMUM VALUE IS ADDED DURING THE MANUFACTURING PHASE
6.6 ECOSYSTEM MAPPING
FIGURE 26 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET: ECOSYSTEM ANALYSIS
6.7 SUPPLY CHAIN ANALYSIS
FIGURE 27 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET: STAKEHOLDERS IN SUPPLY CHAIN
6.8 PORTER’S FIVE FORCES ANALYSIS
TABLE 9 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET: PORTER’S FIVE FORCES ANALYSIS
6.8.1 THREAT OF NEW ENTRANTS
6.8.1.1 High capital requirement
6.8.1.2 High preference for products from well-established brands
6.8.2 THREAT OF SUBSTITUTES
6.8.2.1 Substitute therapies for ERCP procedures
6.8.3 BARGAINING POWER OF SUPPLIERS
6.8.3.1 Presence of several raw material suppliers
6.8.3.2 Supplier switching costs
6.8.4 BARGAINING POWER OF BUYERS
6.8.4.1 Few companies offer premium products at the global level
6.8.5 INTENSITY OF COMPETITIVE RIVALRY
6.8.5.1 Increasing demand for high-quality and innovative products
6.8.5.2 Lucrative growth potential in emerging markets
6.9 REGULATORY ANALYSIS
6.10 PATENT ANALYSIS
6.10.1 PATENT PUBLICATION TRENDS FOR ERCP
FIGURE 28 GLOBAL PATENT PUBLICATION TRENDS IN ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, 2017–2021
6.10.2 TOP APPLICANTS (COMPANIES) OF ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY PATENTS
FIGURE 29 TOP COMPANIES THAT APPLIED FOR ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY PATENTS, 2017–2021
6.10.3 JURISDICTION ANALYSIS: TOP APPLICANTS (COUNTRIES) FOR PATENTS IN ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET
FIGURE 30 JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY PATENTS, 2017–2021
6.11 TRADE ANALYSIS
TABLE 10 NUMBER OF EXPORTS AND IMPORTS RELATED TO ERCP EQUIPMENT
6.12 IMPACT OF COVID-19 ON THE ENDOSCOPY EQUIPMENT MARKET

7 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT (Page No. – 78)
7.1 INTRODUCTION
TABLE 11 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
7.2 ENDOSCOPES
7.2.1 THE RISING PREFERENCE FOR MINIMALLY INVASIVE SURGERIES IS EXPECTED TO DRIVE THE ENDOSCOPES MARKET
TABLE 12 ENDOSCOPES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
7.3 ENDOTHERAPY DEVICES
7.3.1 THESE ARE MINIMALLY INVASIVE DEVICES USED TO TREAT OR DIAGNOSE GI CONDITIONS
TABLE 13 ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 14 ENDOTHERAPY DEVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
7.3.2 SPHINCTEROTOME
7.3.2.1 The risk of bleeding post-sphincterotomy is 2%, with 0.1% mortality
TABLE 15 SPHINCTEROTOME MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
7.3.3 LITHOTRIPTER
7.3.3.1 Lithotripters are used to pulverize stones into smaller pieces so that they can pass out of a body naturally
TABLE 16 LITHOTRIPTER MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
7.3.4 STENTS
7.3.4.1 Metal stents have higher patency rates and are less expensive than plastic stents
TABLE 17 STENTS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
7.3.5 CANNULAS
7.3.5.1 The success rate of ERCP procedures is directly proportional to cannulation
TABLE 18 CANNULAS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
7.3.6 FORCEPS
7.3.6.1 The prevalence of cancer leads to significant demand for biopsy forceps for the collection of tissue samples
TABLE 19 FORCEPS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
7.3.7 SNARES
7.3.7.1 Snares are commonly used for cold or hot polypectomy
TABLE 20 SNARES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
7.3.8 CATHETERS
7.3.8.1 Catheters inject a contrast medium for the visualization of internal tissues
TABLE 21 CATHETERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
7.3.9 GUIDING WIRES
7.3.9.1 The most used guidewires in ERCP come in three different diameters: 0.018, 0.025, and 0.035 inches
TABLE 22 GUIDING WIRES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
7.3.10 BALLOONS
7.3.10.1 Balloon endoscopy involves balloons that inflate and deflate to pinch together the walls of the GI tract
TABLE 23 BALLOONS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
7.3.11 BASKETS
7.3.11.1 Baskets are commonly used instruments for the removal of bile duct stones in ERCP
TABLE 24 BASKETS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
7.4 VISUALIZATION SYSTEMS
7.4.1 VISUALIZATIONS SYSTEMS HAVE APPLICATIONS ACROSS ALL ERCP PROCEDURES
TABLE 25 VISUALIZATION SYSTEMS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
7.5 ENERGY DEVICES
7.5.1 ENERGY DEVICES CAN BE MONOPOLAR OR BIPOLAR
TABLE 26 ENERGY DEVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
7.6 OTHERS
TABLE 27 ERCP ACCESSORIES AND DESCRIPTIONS
TABLE 28 OTHERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)

8 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE (Page No. – 96)
8.1 INTRODUCTION
TABLE 29 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
8.2 BILIARY SPHINCTEROTOMY
8.2.1 INCREASING INCIDENCE RATES OF SOD TO DRIVE THE GROWTH OF THIS SEGMENT
TABLE 30 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET FOR BILIARY SPHINCTEROTOMY, BY COUNTRY, 2019–2026 (USD MILLION)
8.3 BILIARY DILATATION
8.3.1 HIGH-CHOLESTEROL DIETS AND OBESITY ARE THE KEY CAUSES OF GALLSTONES, THUS DRIVING THE UPTAKE OF BILIARY DILATATION PROCEDURES
TABLE 31 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET FOR BILIARY DILATATION, BY COUNTRY, 2019–2026 (USD MILLION)
8.4 BILIARY STENTING
8.4.1 THE RISING PREVALENCE OF GALLBLADDER DISEASES IN THE GROWING GERIATRIC POPULATION IS EXPECTED TO PROPEL THE DEMAND FOR BILIARY STENTS
TABLE 32 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET FOR BILIARY STENTING, BY COUNTRY, 2019–2026 (USD MILLION)
8.5 PANCREATIC SPHINCTEROTOMY
8.5.1 THE RISING INCIDENCE OF PANCREATIC CANCER IS EXPECTED TO DRIVE THE DEMAND FOR THIS PROCEDURE
TABLE 33 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET FOR PANCREATIC SPHINCTEROTOMY, BY COUNTRY, 2019–2026 (USD MILLION)
8.6 PANCREATIC DUCT DILATATION
8.6.1 BALLOON DILATION ALONG WITH ENDOSCOPIC SPHINCTEROTOMY IS THE PREFERRED PROCEDURE FOR STONE REMOVAL
TABLE 34 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET FOR PANCREATIC DUCT DILATATION, BY COUNTRY, 2019–2026 (USD MILLION)
8.7 PANCREATIC DUCT STENTING
8.7.1 PANCREATIC DUCT STENTING IS THE TREATMENT OF CHOICE FOR CHRONIC PANCREATIC DISORDERS
TABLE 35 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET FOR PANCREATIC DUCT STENTING, BY COUNTRY, 2019–2026 (USD MILLION)

9 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER (Page No. – 104)
9.1 INTRODUCTION
TABLE 36 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION)
9.2 HOSPITALS
9.2.1 INCREASING INVESTMENTS BY GOVERNMENT ORGANISATIONS BOOST THE ADOPTION OF ERCP BY THIS END-USER SEGMENT
TABLE 37 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET FOR HOSPITALS, BY COUNTRY, 2019–2026 (USD MILLION)
9.3 AMBULATORY SURGERY CENTERS/CLINICS
9.3.1 AMBULATORY SURGERY CENTERS PROVIDE OUTPATIENT ECRP PROCEDURES THROUGH EFFICIENT OPERATIONS
TABLE 38 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET FOR AMBULATORY SURGERY CENTERS/CLINICS, BY COUNTRY, 2019–2026 (USD MILLION)
9.4 OTHER END USERS
TABLE 39 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET FOR OTHER END USERS, BY COUNTRY, 2019–2026 (USD MILLION)

10 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY REGION (Page No. – 109)
10.1 INTRODUCTION
FIGURE 31 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
TABLE 40 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY REGION, 2019–2026 (USD MILLION)
10.2 NORTH AMERICA
FIGURE 32 NORTH AMERICA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SNAPSHOT
TABLE 41 NORTH AMERICA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 42 NORTH AMERICA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 43 NORTH AMERICA: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 44 NORTH AMERICA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
TABLE 45 NORTH AMERICA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION)
10.2.1 US
10.2.1.1 The large market in the US is mainly driven by high healthcare spending in the country and the increasing incidence of cancer
TABLE 46 MEDICARE NATIONAL AVERAGE COVERAGE FOR OUTPATIENT PROCEDURES, 2020
TABLE 47 LIST OF DEVICES THAT RECEIVED FDA APPROVALS BETWEEN 2018 AND 2021
TABLE 48 US: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 49 US: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 50 US: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
TABLE 51 US: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION)
10.2.2 CANADA
10.2.2.1 High costs of endoscopic retrograde cholangiopancreatography to restrain the market growth in Canada
TABLE 52 INCIDENCE ESTIMATES BY CANCER TYPE (CANADA)
TABLE 53 CANADA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 54 CANADA: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 55 CANADA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
TABLE 56 CANADA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION)
10.3 EUROPE
TABLE 57 EUROPE: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 58 EUROPE: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 59 EUROPE: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 60 EUROPE: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
TABLE 61 EUROPE: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION)
10.3.1 GERMANY
10.3.1.1 Germany’s rising geriatric population is one of the key drivers for the ERCP market
TABLE 62 GERMANY: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 63 GERMANY: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 64 GERMANY: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
TABLE 65 GERMANY: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION)
10.3.2 UK
10.3.2.1 Investments by hospitals to purchase new & advanced ERCP equipment is expected to propel market growth in the UK
TABLE 66 UK: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 67 UK: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 68 UK: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
TABLE 69 UK: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION)
10.3.3 FRANCE
10.3.3.1 High healthcare expenditure is expected to support the growth of the ERCP market in France
TABLE 70 FRANCE: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 71 FRANCE: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 72 FRANCE: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
TABLE 73 FRANCE: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION)
10.3.4 SPAIN
10.3.4.1 Increasing prevalence of cardiovascular diseases in Spain to stimulate the market growth for endoscopes
TABLE 74 SPAIN: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 75 SPAIN: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 76 SPAIN: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
TABLE 77 SPAIN: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION)
10.3.5 ITALY
10.3.5.1 Rising government initiatives for the adoption of advanced medical equipment to drive the market growth for ERCP equipment & procedures in Italy
TABLE 78 ITALY: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 79 ITALY: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 80 ITALY: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
TABLE 81 ITALY: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION)
10.3.6 REST OF EUROPE (ROE)
TABLE 82 ROE: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 83 ROE: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 84 ROE: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
TABLE 85 ROE: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION)
10.4 ASIA PACIFIC
FIGURE 33 ASIA PACIFIC: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SNAPSHOT
TABLE 86 ASIA PACIFIC: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 87 ASIA PACIFIC: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 88 ASIA PACIFIC: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 89 ASIA PACIFIC: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
TABLE 90 ASIA PACIFIC: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION)
10.4.1 JAPAN
10.4.1.1 Supportive medical device reimbursement policies to drive the market growth for ERCP in Japan
TABLE 91 JAPAN ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 92 JAPAN: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 93 JAPAN: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
TABLE 94 JAPAN: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION)
10.4.2 CHINA
10.4.2.1 Large patient population and the strong need for healthcare infrastructure improvements to drive the market growth in China
TABLE 95 CHINA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 96 CHINA: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 97 CHINA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
TABLE 98 CHINA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION)
10.4.3 INDIA
10.4.3.1 Favorable government initiatives for improvements in healthcare infrastructure to support the market growth for ERCP in India
TABLE 99 INDIA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 100 INDIA: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 101 INDIA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
TABLE 102 INDIA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION)
10.4.4 AUSTRALIA
10.4.4.1 The high number of cancer rates in Australia is expected to drive the demand for endoscopy instruments
TABLE 103 AUSTRALIA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 104 AUSTRALIA: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 105 AUSTRALIA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
TABLE 106 AUSTRALIA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION)
10.4.5 REST OF ASIA PACIFIC (ROAPAC)
TABLE 107 ROAPAC: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 108 ROAPAC: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 109 ROAPAC: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
TABLE 110 ROAPAC: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION)
10.5 LATIN AMERICA
10.5.1 THE GOVERNMENTS IN MANY LATIN AMERICAN COUNTRIES ARE FOCUSED ON IMPROVING HEALTHCARE INFRASTRUCTURE, AND IN TURN, THE ADOPTION OF ERCP IS EXPECTED TO RISE
TABLE 111 LATIN AMERICA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 112 LATIN AMERICA: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 113 LATIN AMERICA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
TABLE 114 LATIN AMERICA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION)
10.5.2 MIDDLE EAST
10.5.2.1 Healthcare infrastructural advancements are expected to create the requirement for advanced hospital equipment such as ERCP in the region
TABLE 115 MIDDLE EAST: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 116 MIDDLE EAST: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 117 MIDDLE EAST: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
TABLE 118 MIDDLE EAST: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION)
10.5.3 AFRICA
10.5.3.1 High prevalence of target diseases and initiatives to strengthen endoscopic services in healthcare organizations to propel market growth
TABLE 119 AFRICA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 120 AFRICA: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 121 AFRICA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
TABLE 122 AFRICA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION)

11 COMPETITIVE LANDSCAPE (Page No. – 158)
11.1 OVERVIEW
11.2 KEY PLAYER STRATEGIES/RIGHT-TO-WIN
11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN THE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET
11.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
FIGURE 34 REVENUE ANALYSIS OF KEY PLAYERS IN ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET
11.4 COMPETITIVE BENCHMARKING
TABLE 123 FOOTPRINT OF COMPANIES IN ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET
TABLE 124 PRODUCT AND SERVICE: COMPANY FOOTPRINT (25 COMPANIES)
TABLE 125 END USER: COMPANY FOOTPRINT (25 COMPANIES)
TABLE 126 REGION: COMPANY FOOTPRINT (26 COMPANIES)
11.5 COMPETITIVE LEADERSHIP MAPPING
11.5.1 STAR
11.5.2 EMERGING LEADER
11.5.3 PERVASIVE PLAYER
11.5.4 PARTICIPANT
FIGURE 35 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET: COMPETITIVE LEADERSHIP MAPPING (2020)
11.6 COMPETITIVE LEADERSHIP MAPPING FOR OTHER COMPANIES
11.6.1 PROGRESSIVE COMPANY
11.6.2 DYNAMIC COMPANY
11.6.3 STARTING BLOCK
11.6.4 RESPONSIVE COMPANY
FIGURE 36 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET: COMPETITIVE LEADERSHIP MAPPING FOR OTHER COMPANIES (2020)
11.7 MARKET RANKING ANALYSIS
FIGURE 37 ERCP MARKET RANKING ANALYSIS, BY PLAYER, 2020
FIGURE 38 ENDOTHERAPY DEVICES MARKET RANKING ANALYSIS, BY PLAYER, 2020
11.8 COMPETITIVE SCENARIO
TABLE 127 PRODUCT LAUNCHES & APPROVALS, 2019–2021
TABLE 128 DEALS, 2019–2021

12 COMPANY PROFILES (Page No. – 173)
(Business overview, Products offered, Recent developments, MnM view, Right to win, Weakness and competitive threats, and Strategic choices made)*
12.1 KEY PLAYERS
12.1.1 OLYMPUS CORPORATION
TABLE 129 OLYMPUS CORPORATION: BUSINESS OVERVIEW
FIGURE 39 COMPANY SNAPSHOT: OLYMPUS CORPORATION (2020)
12.1.2 CONMED CORPORATION
TABLE 130 CONMED CORPORATION: BUSINESS OVERVIEW
FIGURE 40 COMPANY SNAPSHOT: CONMED CORPORATION (2020)
12.1.3 AMBU A/S
TABLE 131 AMBU A/S: BUSINESS OVERVIEW
FIGURE 41 COMPANY SNAPSHOT: AMBU A/S (2020)
12.1.4 BOSTON SCIENTIFIC CORPORATION
TABLE 132 BOSTON SCIENTIFIC CORPORATION: BUSINESS OVERVIEW
FIGURE 42 COMPANY SNAPSHOT: BOSTON SCIENTIFIC CORPORATION (2020)
12.1.5 JOHNSON & JOHNSON
TABLE 133 JOHNSON & JOHNSON: BUSINESS OVERVIEW
FIGURE 43 COMPANY SNAPSHOT: JOHNSON & JOHNSON (2020)
12.1.6 FUJIFILM HOLDINGS CORPORATION
TABLE 134 FUJIFILM HOLDINGS CORPORATION: BUSINESS OVERVIEW
FIGURE 44 COMPANY SNAPSHOT: FUJIFILM HOLDINGS CORPORATION (2020)
12.1.7 MEDTRONIC, PLC
TABLE 135 MEDTRONIC, PLC: BUSINESS OVERVIEW
FIGURE 45 COMPANY SNAPSHOT: MEDTRONIC, PLC (2020)
12.1.8 KARL STORZ SE & CO. KG
TABLE 136 KARL STORZ SE & CO. KG.: BUSINESS OVERVIEW
12.1.9 COOK MEDICAL
TABLE 137 COOK MEDICAL: BUSINESS OVERVIEW
12.1.10 HOYA CORPORATION
TABLE 138 HOYA CORPORATION: BUSINESS OVERVIEW
FIGURE 46 COMPANY SNAPSHOT: HOYA CORPORATION (2020)
12.1.11 B. BRAUN MELSUNGEN AG
TABLE 139 B. BRAUN MELSUNGEN AG: BUSINESS OVERVIEW
FIGURE 47 COMPANY SNAPSHOT: B. BRAUN MELSUNGEN AG (2020)
12.1.12 HOBBS MEDICAL, INC.
TABLE 140 HOBBS MEDICAL, INC.: BUSINESS OVERVIEW
12.1.13 STERIS PLC
FIGURE 48 COMPANY SNAPSHOT: STERIS PLC (2020)
TABLE 141 STERIS PLC: BUSINESS OVERVIEW
12.1.14 MERIT MEDICAL SYSTEMS, INC.
TABLE 142 MERIT MEDICAL SYSTEMS, INC.: BUSINESS OVERVIEW
FIGURE 49 COMPANY SNAPSHOT: MERIT MEDICAL SYSTEMS, INC. (2020)
12.1.15 TELEMED SYSTEMS, INC.
TABLE 143 TELEMED SYSTEMS, INC.: BUSINESS OVERVIEW
12.1.16 CHANGZHOU HEALTH MICROPORT MEDICAL DEVICE CO., LTD.
TABLE 144 CHANGZHOU HEALTH MICROPORT MEDICAL DEVICE CO., LTD.: BUSINESS OVERVIEW
12.1.17 MEDI-GLOBE GMBH
TABLE 145 MEDI-GLOBE GMBH: BUSINESS OVERVIEW
12.1.18 TAEWOONG MEDICAL CO., LTD.
TABLE 146 TAEWOONG MEDICAL CO., LTD.: BUSINESS OVERVIEW
12.1.19 HUGER MEDICAL INSTRUMENT CO., LTD.
TABLE 147 HUGER MEDICAL INSTRUMENT CO., LTD..: BUSINESS OVERVIEW
12.1.20 INTROMEDIC CO., LTD.
TABLE 148 INTROMEDIC CO., LTD.: BUSINESS OVERVIEW
FIGURE 50 COMPANY SNAPSHOT: INTROMEDIC CO., LTD. (2020)
12.1.21 SONOSCAPE MEDICAL CORP.
TABLE 149 SONOSCAPE MEDICAL CORP.: BUSINESS OVERVIEW
FIGURE 51 COMPANY SNAPSHOT: SONOSCAPE MEDICAL CORP (2020)
12.2 OTHER PLAYERS
*Details on Business overview, Products offered, Recent developments, MnM view, Right to win, Weakness and competitive threats, and Strategic choices made might not be captured in case of unlisted companies.

13 APPENDIX (Page No. – 230)
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 AVAILABLE CUSTOMIZATIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS


    • 리포트 제목은 자동으로 입력됩니다.
    • *항목은 필수항목입니다.

    의뢰분류*

    성함*

    회사명*

    부서명

    이메일*

    전화번호

    저희 사이트를 알게 된 경로를 가르쳐 주세요.

    문의 내용*

     

    ※개인정보보호정책은여기에서 확인 가능합니다。

    Email 문의도 받고 있습니다.
    아래 주소이며 죄송하지만 "(at)"을 "@"로 바꾸어 보내주시길 부탁드립니다.
    mooneui(at)chosareport-korea.com